Elucent Medical, an Eden Prairie, MN-based medical technology company working in the field of surgical navigation through in-site spatial intelligence (iSI), raised $42.5M in Series C funding.
The round was led by Vensana Capital and RC Capital with participation from existing investors. In conjunction with the funding, Greg Banker and Kirk Nielsen of Vensana Capital and Scott Steever of RC Capital, joined the board.
The company intends to use the funds to further propel the development and commercialization of its EnVisio® and SmartClip® technologies for tissue sparing oncologic surgery.
Led by Jason Pesterfield, President and CEO, Elucent Medical is a provider of oncologic surgical treatment solutions. Its flagship technologies, EnVisio and SmartClip, offer solutions for intelligent spatial guidance (iSG).
EnVisio® leverages proprietary technology that converts existing surgical tools to smart navigated instruments that can be tracked in real-time and guided with millimeter precision. EnVisio is currently optimized to guide the surgical treatment of breast cancer, while adoption of the technology has expanded to address other soft tissue oncology surgeries. In addition, Elucent is currently developing products to assist surgeons in their pursuit of margin negative resections in lung and other soft tissue clinical applications, and these products also integrate with existing tools and minimally invasive solutions, including video and robotic-assisted medical technologies.
Commenting on the news, Jason Pesterfield said: “We are proud to have secured this substantial funding, which will advance our mission to radically change the way surgeons mark and locate their intended target for removal by turning their existing surgical instruments into intelligent tracking devices that elevate the standard of care in soft tissue oncologic procedures.”
FinSMEs
10/04/2024